Urovant Sciences Announces Upcoming Presentations of Data from Phase 2b Trial of Vibegron in Patients with Overactive Bladder
- Urovant Sciences, today announced that clinical data from a Phase 2b study of vibegron will be presented at two upcoming medical congresses.
- Eight-week results from the vibegron dose-ranging trial will be presented at the 2018 Winter Meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU)
BASEL, Switzerland and IRVINE, Calif., February 28, 2018 /PRNewswire/ — Urovant Sciences, a global biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that clinical data from a Phase 2b study of vibegron will be presented at two upcoming medical congresses.
Eight-week results from the vibegron dose-ranging trial will be presented at the 2018 Winter Meeting of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), which is being held February 27-March 3 in Austin, Texas. In addition, 52-week data from an extension of the same vibegron trial will be presented at the 113th Annual Meeting of the American Urological Association (AUA), which is being held May 18-21 in San Francisco, California.
Details for both presentations are as follows:
SUFU Oral Presentation
- Date and Time: March 3, 2018 at 8:10 a.m. CT
- Abstract (#34): Vibegron, a Novel Once Daily Oral β-3 Agonist, Significantly Reduces Average Daily Micturitions, Urge Incontinence Episodes and Urgency Episodes in Patients with Overactive Bladder
- Location: Austin, Texas
- Presenter: David Mitcheson
AUA Oral Presentation
- Date and Time: May 20, 2018 at 3:30 p.m. PT
- Abstract (#18-2878): Durable Efficacy and Safety of Long-Term Once-Daily Vibegron, A Novel Oral β-3 Adrenergic Receptor Agonist: A 52-Week Phase 2 Study in Patients with Overactive Bladder Symptoms
- Location: San Francisco, California
- Presenter: Roger Dmochowski
About Overactive Bladder
Overactive bladder (OAB) is a condition that affects as many as 46 million adults in the United States alone. The most common symptoms of OAB include the experience of sudden urges to urinate that cannot be controlled, frequent urination, and urinary incontinence due to involuntary contractions of the detrusor muscle. While several conditions may contribute to signs and symptoms of overactive bladder, the underlying cause of OAB remains unclear.
Vibegron is an investigational oral β3-adrenergic agonist being studied for the treatment of OAB. β3-adrenergic receptors play a role in the bladder fill-void cycle. By stimulating that pathway, vibegron has the potential to relax the bladder detrusor muscle. Relaxing the bladder allows it to store urine more efficiently, thereby decreasing the symptoms of OAB. Over 2,700 patients with symptoms of OAB have previously been enrolled in clinical studies evaluating the safety and efficacy of vibegron.
About Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions. Urovant’s lead therapeutic candidate is vibegron, a selective β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant intends to develop treatments for additional urologic diseases. For more information, please visit urovant.staging.wpengine.com.